VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing

被引:21
作者
Meeson, Richard [1 ,2 ]
Sanghani-Keri, Anita [1 ]
Coathup, Melanie [1 ,3 ]
Blunn, Gordon [1 ,4 ]
机构
[1] Univ Coll London, Div Surg, Stanmore, Middx, England
[2] Royal Vet Coll, Hatfield, Herts, England
[3] Univ Cent Florida, Orlando, FL 32816 USA
[4] Univ Portsmouth, Portsmouth, Hants, England
基金
英国医学研究理事会;
关键词
mobilization; mesenchymal stem cells; AMD3100; VEGF; fracture healing; BONE-MARROW; PERIPHERAL-BLOOD; PROGENITOR CELLS; IN-VIVO; BIOLOGICAL CHARACTERISTICS; PRECURSOR CELLS; ANGIOGENESIS; MIGRATION; REPAIR; ANTAGONIST;
D O I
10.1002/jor.24164
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
A significant number of fractures develop non-union. Mesenchymal stem cell (MSC) therapy may be beneficial, however, this requires cell acquisition, culture and delivery. Endogenous mobilization of stem cells offers a non-invasive alternative. The hypothesis was administration of VEGF and the CXCR4 antagonist AMD3100 would increase the circulating pool of available MSCs and improve fracture healing. Ex-breeder female wistar rats received VEGF followed by AMD3100, or sham PBS. Blood prepared for culture and colonies were counted. P3 cells were analyzed by flow cytometry, bi-differentiation. The effect of mobilization on fracture healing was evaluated with 1.5 mm femoral osteotomy stabilized with an external fixator in 12-14 week old female Wistars. The mobilized group had significantly greater number of cfus/ml compared to controls, p = 0.029. The isolated cells expressed 1.8% CD34, 35% CD45, 61% CD29, 78% CD90, and differentiated into osteoblasts but not into adipocytes. The fracture gap in animals treated with VEGF and AMD3100 showed increased bone volume; 5.22 +/- 1.7 mu m(3) and trabecular thickness 0.05 +/- 0.01 mu m compared with control animals (4.3 +/- 3.1 mu m(3), 0.04 +/- 0.01 mu m, respectively). Radiographic scores quantifying fracture healing (RUST) showed that the animals in the mobilization group had a higher healing score compared to controls (9.6 vs. 7.7). Histologically, mobilization resulted in significantly lower group variability in bone formation (p = 0.032) and greater amounts of bone and less fibrous tissue than the control group. Clinical significance: This pre-clinical study demonstrates a beneficial effect of endogenous MSC mobilization on fracture healing, which may have translation potential to prevent or treat clinical fractures at risk of delayed or non-union fractures. (c) 2018 The Authors. Journal of Orthopaedic Research (R) Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research Society. J Orthop Res 37:1294-1302, 2019.
引用
收藏
页码:1294 / 1302
页数:9
相关论文
共 43 条
[1]   Circulating Plastic Adherent Mesenchymal Stem Cells in Aged Hip Fracture Patients [J].
Alm, Jessica J. ;
Koivu, Helka M. A. ;
Heino, Terhi J. ;
Hentunen, Teuvo A. ;
Laitinen, Saara ;
Aro, Hannu T. .
JOURNAL OF ORTHOPAEDIC RESEARCH, 2010, 28 (12) :1634-1642
[2]   The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine [J].
Bianco, Paolo ;
Cao, Xu ;
Frenette, Paul S. ;
Mao, Jeremy J. ;
Robey, Pamela G. ;
Simmons, Paul J. ;
Wang, Cun-Yu .
NATURE MEDICINE, 2013, 19 (01) :35-42
[3]   Markers for Characterization of Bone Marrow Multipotential Stromal Cells [J].
Boxall, Sally A. ;
Jones, Elena .
STEM CELLS INTERNATIONAL, 2012, 2012
[4]   Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist [J].
Broxmeyer, HE ;
Orschell, CM ;
Clapp, DW ;
Hangoc, G ;
Cooper, S ;
Plett, PA ;
Liles, WC ;
Li, XX ;
Graham-Evans, B ;
Campbell, TB ;
Calandra, G ;
Bridger, G ;
Dale, DC ;
Srour, EF .
JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (08) :1307-1318
[5]   The AMD3100 story: The path to the discovery of a stem cell mobilizer (Mozobil) [J].
De Clercq, Erik .
BIOCHEMICAL PHARMACOLOGY, 2009, 77 (11) :1655-1664
[6]   Growth factors in bone repair. [J].
Devescovi V. ;
Leonardi E. ;
Ciapetti G. ;
Cenni E. .
La Chirurgia degli Organi di Movimento, 2008, 92 (3) :161-168
[7]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[8]   Influence of age on rat bone-marrow mesenchymal stem cells potential [J].
Fafian-Labora, J. ;
Fernandez-Pernas, P. ;
Fuentes, I. ;
De Toro, J. ;
Oreiro, N. ;
Sangiao-Alvarellos, S. ;
Mateos, J. ;
Arufe, M. C. .
SCIENTIFIC REPORTS, 2015, 5
[9]   HETEROTOPIC TRANSPLANTS OF BONE MARROW - ANALYSIS OF PRECURSOR CELLS FOR OSTEOGENIC AND HEMATOPOIETIC TISSUES [J].
FRIEDENSTEIN, AJ ;
PETRAKOVA, KV ;
KUROLESOVA, AI ;
FROLOVA, GP .
TRANSPLANTATION, 1968, 6 (02) :230-+
[10]  
Fu WL, 2015, TISSUE ENG PART C-ME, V21, P1088, DOI [10.1089/ten.tec.2014.0595, 10.1089/ten.TEC.2014.0595]